Bellevue Life Sciences Acquisition Corp.
Status: Live Deal
U=S+W+R
W=S@11.5
R=S/10
| IPO Proceeds, $M | $69.00M |
|---|---|
| IPO Date | Feb 10, 2023 |
| CEO | Kuk Hyoun Hwang |
| Left Lead | Chardan |
| IPO Cash in Trust | 101.8% |
| SPAC Tenor | 9 + 6 + 6 + 3 |
| IPO Sector |
Healthcare
Healthcare industry, more specifically in the biotechnology sector |
| IPO Geography | Global |
| Target Company | OSR Holdings |
| Deal Announced | Nov 16, 2023 |
| Deal Size, $M | TBD |
| Deal Sector | Healthcare |
| Deal Geography | Global |
| SEC Filings | www.sec.gov |
| Approval Vote | TBD |
| Amendment Vote | Nov 12, 2024 |
BLAC
BLACU
BLACW
BLACR
| Price | $11.60 |
|---|---|
| Last closing price | $11.66 |
| H/L, today | $11.57 / $12.96 |
| H/L, 52-week | $10.07 / $10.71 |
| Volume, today | 24,553 |
| Volume, 3-month avg. | N/A |
Sign up for Free Trial
No credit card required
Sign in for more on Bellevue Life Sciences Acquisition Corp.:
- Structure and cap table
- 6 directors & officers
- 34 filings and events
- 2 underwriters
Structure
Sign in to view structure, cap table, and calendar of events.
Team
| Name | Age | Title |
|---|---|---|
| Kuk Hyoun Hwang | 47 | CEO and Director |
| David J. Yoo | 49 | CFO |
| Jun Chul Whang | 58 | Director |
| Phil Geon Lee | 56 | Director |
| Jin Whan Park | 55 | Director |
| Sang Hyun Kim | 53 | Director |
Sign in to view team biographies and more sponsor and affiliate data.
Advisors
Underwriters
| Chardan | BR | 5,950,000 | units |
| B. Riley FBR | 50,000 | ||
| 6,000,000 | units | ||
| Up-Front UW fee | 2.00 | % | |
| Deferred UW fee |
3.00 | % |
Sign in to view more advisor data.